Showing results (821-830 of 1,877) with videos related to

Sort By:
Pageof 188
Immunotherapy|July 14, 2012
Sinomenine can prolong high-risk corneal graft survival in a rat modelYing Wang, Dongli Ma, Ying Jie, et al.
Immunotherapy|July 14, 2012
Immunotherapy for gastric premalignant lesions and cancerValerio Zorzetto, Gemma Maddalo, Daniela Basso, et al.
Immunotherapy|July 14, 2012
Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulationsLinda Cox, Moisés Calderón, Oliver Pfaar
Immunotherapy|August 3, 2012
Effects of chitosan and its derivative added to water on immunological enhancement and disease controlShyh-Shyan Jan, Deng-Cheng Liu, Xiao-Ying Dong, et al.
Immunotherapy|October 22, 2021
Thirty-day mortality rates after immunotherapy initiationOsman Sütcüoğlu, Ayşegül İlhan, Seher Yıldız Tacar, et al.
Immunotherapy|January 25, 2022
Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancerBalazs Halmos, Thomas Burke, Chrysostomos Kalyvas, et al.
Immunotherapy|May 16, 2018
Efficacy, safety and quality of life in patients receiving subcutaneous IgG treatment: experience in Bogotá, ColombiaMaría Claudia Ortega-López, Javier Garay, Mónica León Pinilla
Immunotherapy|August 29, 2018
Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophagesPing Zhang, Songbo Zhao, Chao Wu, et al.
Immunotherapy|August 29, 2018
Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature reviewLingdi Zhao, Yonghao Yang, Wei Li, et al.
Immunotherapy|June 12, 2019
First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatmentVamsidhar Velcheti, Sheenu Chandwani, Xin Chen, et al.
Pageof 188